Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.
Approximately 10% to 20% of isoniazid recipients manifest biochemical evidence of liver injury. A smaller number of patients develop clinically overt hepatitis. Isoniazid is metabolized in man at extremely variable rates, and the rate is under genetic control. Two separate clinical studies have noted a possible relation between susceptibility of patients to isoniazid liver injury and rapid metabolism (acetylation) of the drug. For this reason, 21 patients who had recovered from probable isoniazid hepatitis and 5 patients who previously had manifested biochemical evidence of mild isoniazid liver injury were genetically phenotyped as rapid or slow isoniazid acetylators by the sulfamethazine method. The rapid phenotype was found in 86% of patients with probable hepatitis and in 60% of the possible ones, whereas the expected frequency was 45%. Eximination of isoniazid metabolites revealed that rapid acetylators hydrolze much more isoniazid to isonic otinic hydrazine moiety than do slow acetylators. The hydrazine moiety liberated from isoniazed is primarily acetylhydrazine, and studies in animals show this metabolite to be converted to a potent acylating agent that produces liver necrosis. We suggest that release of the hepatotoxic hydrazino moiety of isoniazid in man is responsible for isoniazid liver injury.
D000107:Acetylation; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D006801:Humans; D006834:Hydrazines / Q000378:metabolism*; D007538:Isoniazid / Q000009:adverse effects* / Q000378:metabolism; D007656:Ketoglutaric Acids / Q000378:metabolism; D008297:Male; D010641:Phenotype; D011773:Pyruvates / Q000378:metabolism
D006834:Hydrazines; D007656:Ketoglutaric Acids; D011773:Pyruvates; D007538:Isoniazid